Developer docs
API playgroundTry for free, no card

Search company profiles

Cresilon

Full company profile

uuid0000543

Namestring
Cresilon
Legal namestring
Cresilon, Inc.
Websiteurl
cresilon.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Cresilon is a Brooklyn-based biotechnology company founded in 2010 by Joe Landolina and Isaac Miller that develops and manufactures proprietary plant-based hemostatic gel products for both human trauma care and veterinary surgical applications. Its core technology is a hydrogel composed of refined algal polysaccharides that forms a mechanical barrier at wound sites, achieving hemostasis in seconds without preparation, manual pressure, or animal-derived components. The product portfolio comprises three FDA-cleared or in-commercialization brands built on a single platform: Cresilon Hemostatic Gel (CHG), cleared in June 2023 for minor cuts and abrasions; TRAUMAGEL, a 30 mL pre-filled syringe FDA 510(k) cleared in August 2024 (K233762) for temporary external control of moderate to severe bleeding; and VETIGEL, a 5 mL veterinary hemostatic gel launched in 2020 and used in over 65,000 procedures worldwide. Cresilon holds ISO 13485:2016 certification and operates a 55,000 sq ft GMP-certified biomanufacturing facility in Brooklyn's Industry City — the only GMP-certified biotech manufacturer in all five boroughs of New York City — with annual production capacity of approximately 300,000 syringes.

The company's revenue model is hardware product sales through a multi-channel distribution network. TRAUMAGEL sells exclusively through authorized medical distributors (Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, ADS Inc.) to EMS agencies, fire departments, Level 1 trauma centers, and military medical units, with a Vizient GPO Innovative Technology contract awarded in March 2026 expanding hospital access. VETIGEL distributes exclusively through Zomedica in the U.S. (under a license-and-supply agreement signed January 2025) and through Covetrus in Europe/UK, McCarthy Vet in Canada, and VerticalVet's 1,800 GPO clinics. Pricing is quote-based and not publicly disclosed. The company has raised over $100 million in cumulative funding across Series A rounds, including a $38.5M Series A-3 (September 2021) and a $25M Series A-4 led by Paulson Investment Company (October 2022), plus a $17M growth round in 2025. Revenue is not publicly disclosed. End customers include Cobb County Fire & EMS, Orangeburg County EMS, Level 1 trauma centers in Denver, Louisiana State University Health Science Center, and veterinary surgical practices across North America, Europe, and Japan.

Short descriptiontext

Cresilon is a Brooklyn-based medical device company that develops and manufactures proprietary plant-based hemostatic gel products — TRAUMAGEL for human trauma care and VETIGEL for veterinary surgery — distributed through authorized medical distributors, channel partners, and GPOs to EMS agencies, trauma hospitals, military, and veterinary clinics worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBrooklyn, United States
HQ citystring
Brooklyn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hemostatic wound care, plant-based hydrogel, emergency trauma devices, veterinary hemostasis, biopolymer medical devices
Industry2 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAMAFAO
Practice Consumables & General Medical Supplies (Needles, Syringes, Gloves, Swabs)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies
NAICS code1 code
  • Adhesive Manufacturing325520
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Hemostatic Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1VETIGEL Product Sales
TypeHardware Sales
Description

Direct product sales of VETIGEL hemostatic gel to veterinary surgeons and clinics through distribution partners including Zomedica (exclusive U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK), and VerticalVet (GPO). Supplied in pre-filled 5mL syringes.

cresilon.com
2TRAUMAGEL Product Sales
TypeHardware Sales
Description

Sales of TRAUMAGEL to EMS agencies, first responders, emergency departments, and trauma centers through authorized distributors. Supplied in sterile 30mL pre-filled syringes. Products available through Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, and ADS, Inc.

cresilon.com
3Licensing & Supply Agreement with Zomedica
TypeLicensing Royalties
Description

Zomedica has exclusive license to market and sell VETIGEL in the U.S. and non-exclusive license internationally. Cresilon supplies product to Zomedica for distribution to U.S. customers.

cresilon.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels10 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details2 tiers
1TRAUMAGEL 30mL Syringe - Quote-based pricing through distributors
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed. Available through authorized medical distributors including Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, and ADS, Inc.

cresilon.com
2VETIGEL 5mL Syringe - Quote-based pricing through distributors
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed. Available through Zomedica (U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK), and VerticalVet GPO members.

cresilon.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1TRAUMAGEL
Description

Hemostatic gel for temporary external use to control moderate to severe bleeding in humans. FDA 510(k) cleared for EMS, trauma hospitals, military, and law enforcement.

cresilon.com
+2 more records
Core offering1 text field

Cresilon develops and manufactures proprietary plant-based hemostatic gel products that stop external bleeding in seconds. The portfolio includes TRAUMAGEL (30 mL pre-filled syringe, FDA 510(k) cleared for moderate-to-severe bleeding in EMS, trauma hospitals, military and law enforcement), VETIGEL (5 mL pre-filled syringe for veterinary surgical hemostasis), and Cresilon Hemostatic Gel (CHG) for minor cuts, lacerations and abrasions. All products leverage the same proprietary biopolymer hydrogel platform and are produced at the company's GMP-certified Brooklyn, NY biomanufacturing facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Saves at least one life per day on average across U.S. deployment
+4 more records
Product overview1 text field

Cresilon develops and manufactures proprietary plant-based hemostatic gel technology that stops bleeding in seconds. The product portfolio consists of two main brands: TRAUMAGEL for human trauma care (FDA 510(k) cleared for temporary external use to control moderate to severe bleeding) delivered in 30 mL syringes, and VETIGEL for veterinary applications delivered in 5 mL syringes. A third product, Cresilon Hemostatic Gel (CHG), received FDA clearance in 2023 for minor wound care. All products utilize the same proprietary hydrogel technology platform but are differentiated by indication, dosage, and regulatory clearance status.

Product and service3 records
1TRAUMAGEL
CategoryHemostatic Medical Device (Human Trauma)
Description

TRAUMAGEL is a hemostatic gel supplied in a sterile individually pouched 30 mL pre-filled syringe. It is FDA 510(k) cleared for temporary external use to control moderate to severe bleeding, requires no preparation, and achieves hemostasis in seconds by forming a mechanical barrier at the wound site. It is sold to licensed healthcare providers via authorized U.S. medical distributors.

2VETIGEL
CategoryHemostatic Medical Device (Veterinary)
Description

VETIGEL is Cresilon's first hemostatic gel in the veterinary market, supplied in a 5 mL pre-filled syringe and made from plant-based polymers. It is designed to stop bleeding in seconds for veterinary surgical procedures and has been used in over 65,000 veterinary procedures worldwide. It is sold via Zomedica (exclusive U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK) and the VerticalVet GPO.

3Cresilon Hemostatic Gel (CHG)
CategoryHemostatic Medical Device (Minor Wound Care)
Description

Cresilon Hemostatic Gel (CHG) is Cresilon's first FDA-cleared hemostatic gel for human use, indicated for the local management of bleeding wounds such as minor cuts, lacerations, and abrasions. It leverages the same proprietary plant-based hydrogel technology platform as TRAUMAGEL and VETIGEL.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-02
Description

Innovative Technology contract awarded to TRAUMAGEL based on expert reviews from hospital experts serving on Vizient's client-led councils. Vizient is the nation's largest provider-driven healthcare performance improvement company representing over $156 billion in annual purchasing volume.

2McCarthy Vet
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-16
Description

McCarthy Vet is Cresilon's first veterinary distribution partner in Canada. McCarthy Vet, a family-owned company serving Canadian veterinarians for over 60 years, distributes VETIGEL directly to veterinary surgeons in Canada.

cresilon.com
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-07
Description

Zomedica has exclusive license to market and sell VETIGEL hemostatic gel in the U.S. and non-exclusive license internationally. Cresilon supplies product to Zomedica for distribution to U.S. customers through Zomedica's established field sales team and trade programs.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-06-11
Description

Preferred Partnership Agreement providing VerticalVet's 1,800 GPO member veterinary clinics access to VETIGEL. VerticalVet is a Group Resource Community offering customized education, data insights, and tailored partner solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-05-20
Description

International distribution agreement for VETIGEL making the product available in Europe and the UK through Covetrus's distribution network.

6Walter Reed Army Institute of Research (WRAIR)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-27
Description

Cooperative Research and Development Agreement (CRADA) to study Cresilon's hemostatic gel technology as a potential field and prehospital treatment for penetrating traumatic brain injury (TBI). First phase preclinical study demonstrated promising safety and efficacy results.

cresilon.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cresilon

Hemostatic Medical Devicescresilon.com

Cresilon is a Brooklyn-based medical device company that develops and manufactures proprietary plant-based hemostatic gel products — TRAUMAGEL for human trauma care and VETIGEL for veterinary surgery — distributed through authorized medical distributors, channel partners, and GPOs to EMS agencies, trauma hospitals, military, and veterinary clinics worldwide.

What Cresilon does

Cresilon is a Brooklyn-based biotechnology company founded in 2010 by Joe Landolina and Isaac Miller that develops and manufactures proprietary plant-based hemostatic gel products for both human trauma care and veterinary surgical applications. Its core technology is a hydrogel composed of refined algal polysaccharides that forms a mechanical barrier at wound sites, achieving hemostasis in seconds without preparation, manual pressure, or animal-derived components. The product portfolio comprises three FDA-cleared or in-commercialization brands built on a single platform: Cresilon Hemostatic Gel (CHG), cleared in June 2023 for minor cuts and abrasions; TRAUMAGEL, a 30 mL pre-filled syringe FDA 510(k) cleared in August 2024 (K233762) for temporary external control of moderate to severe bleeding; and VETIGEL, a 5 mL veterinary hemostatic gel launched in 2020 and used in over 65,000 procedures worldwide. Cresilon holds ISO 13485:2016 certification and operates a 55,000 sq ft GMP-certified biomanufacturing facility in Brooklyn's Industry City — the only GMP-certified biotech manufacturer in all five boroughs of New York City — with annual production capacity of approximately 300,000 syringes.

The company's revenue model is hardware product sales through a multi-channel distribution network. TRAUMAGEL sells exclusively through authorized medical distributors (Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, ADS Inc.) to EMS agencies, fire departments, Level 1 trauma centers, and military medical units, with a Vizient GPO Innovative Technology contract awarded in March 2026 expanding hospital access. VETIGEL distributes exclusively through Zomedica in the U.S. (under a license-and-supply agreement signed January 2025) and through Covetrus in Europe/UK, McCarthy Vet in Canada, and VerticalVet's 1,800 GPO clinics. Pricing is quote-based and not publicly disclosed. The company has raised over $100 million in cumulative funding across Series A rounds, including a $38.5M Series A-3 (September 2021) and a $25M Series A-4 led by Paulson Investment Company (October 2022), plus a $17M growth round in 2025. Revenue is not publicly disclosed. End customers include Cobb County Fire & EMS, Orangeburg County EMS, Level 1 trauma centers in Denver, Louisiana State University Health Science Center, and veterinary surgical practices across North America, Europe, and Japan.

Cresilon firmographics

Firmographics
Name
Cresilon
Legal name
Cresilon, Inc.
Website
https://cresilon.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Cresilon is a Brooklyn-based medical device company that develops and manufactures proprietary plant-based hemostatic gel products — TRAUMAGEL for human trauma care and VETIGEL for veterinary surgery — distributed through authorized medical distributors, channel partners, and GPOs to EMS agencies, trauma hospitals, military, and veterinary clinics worldwide.
Ownership category
akta.pro rank

Cresilon industry classification

Industry
Product category
Hemostatic Medical Devices
NAICS
Adhesive Manufacturing (325520)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAMAFAO
Practice Consumables & General Medical Supplies (Needles, Syringes, Gloves, Swabs)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Medical Devices & Supplies

Keywords

  • Hemostatic wound care
  • Plant-based hydrogel
  • Emergency trauma devices
  • Veterinary hemostasis
  • Biopolymer medical devices

Where Cresilon is headquartered

Location

Headquarters

HQ city
Brooklyn
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cresilon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. VETIGEL Product Sales: Direct product sales of VETIGEL hemostatic gel to veterinary surgeons and clinics through distribution partners including Zomedica (exclusive U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK), and VerticalVet (GPO). Supplied in pre-filled 5mL syringes.
  2. TRAUMAGEL Product Sales: Sales of TRAUMAGEL to EMS agencies, first responders, emergency departments, and trauma centers through authorized distributors. Supplied in sterile 30mL pre-filled syringes. Products available through Pacific Biomedical, Life-Assist, Bound Tree, Henry Schein, and ADS, Inc.
  3. Licensing & Supply Agreement with Zomedica: Zomedica has exclusive license to market and sell VETIGEL in the U.S. and non-exclusive license internationally. Cresilon supplies product to Zomedica for distribution to U.S. customers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goTRAUMAGEL 30mL Syringe - Quote-based pricing through distributors
Unit PricingPay-as-you-goVETIGEL 5mL Syringe - Quote-based pricing through distributors

Go-to-market motion3 records

Distribution channels10 records

Marketing channels6 records

Cresilon product offering

Product offering

Core offering

Cresilon develops and manufactures proprietary plant-based hemostatic gel products that stop external bleeding in seconds. The portfolio includes TRAUMAGEL (30 mL pre-filled syringe, FDA 510(k) cleared for moderate-to-severe bleeding in EMS, trauma hospitals, military and law enforcement), VETIGEL (5 mL pre-filled syringe for veterinary surgical hemostasis), and Cresilon Hemostatic Gel (CHG) for minor cuts, lacerations and abrasions. All products leverage the same proprietary biopolymer hydrogel platform and are produced at the company's GMP-certified Brooklyn, NY biomanufacturing facility.

Product overview

Cresilon develops and manufactures proprietary plant-based hemostatic gel technology that stops bleeding in seconds. The product portfolio consists of two main brands: TRAUMAGEL for human trauma care (FDA 510(k) cleared for temporary external use to control moderate to severe bleeding) delivered in 30 mL syringes, and VETIGEL for veterinary applications delivered in 5 mL syringes. A third product, Cresilon Hemostatic Gel (CHG), received FDA clearance in 2023 for minor wound care. All products utilize the same proprietary hydrogel technology platform but are differentiated by indication, dosage, and regulatory clearance status.

Differentiator

Problem solved

Functional benefit

Brands

  • TRAUMAGEL: Hemostatic gel for temporary external use to control moderate to severe bleeding in humans. FDA 510(k) cleared for EMS, trauma hospitals, military, and law enforcement.
  • VETIGEL
  • Cresilon Hemostatic Gel (CHG)

Products and services

  • TRAUMAGEL TRAUMAGEL is a hemostatic gel supplied in a sterile individually pouched 30 mL pre-filled syringe. It is FDA 510(k) cleared for temporary external use to control moderate to severe bleeding, requires no preparation, and achieves hemostasis in seconds by forming a mechanical barrier at the wound site. It is sold to licensed healthcare providers via authorized U.S. medical distributors.
  • VETIGEL VETIGEL is Cresilon's first hemostatic gel in the veterinary market, supplied in a 5 mL pre-filled syringe and made from plant-based polymers. It is designed to stop bleeding in seconds for veterinary surgical procedures and has been used in over 65,000 veterinary procedures worldwide. It is sold via Zomedica (exclusive U.S.), McCarthy Vet (Canada), Covetrus (Europe/UK) and the VerticalVet GPO.
  • Cresilon Hemostatic Gel (CHG) Cresilon Hemostatic Gel (CHG) is Cresilon's first FDA-cleared hemostatic gel for human use, indicated for the local management of bleeding wounds such as minor cuts, lacerations, and abrasions. It leverages the same proprietary plant-based hydrogel technology platform as TRAUMAGEL and VETIGEL.

Quantifiable outcome

  • Saves at least one life per day on average across U.S. deployment
  • +4 more outcomes

Companies that use Cresilon

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Cresilon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cresilon partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • VizientcoreChannel Partner/ Reseller/ Distributor · 2 March 2026Innovative Technology contract awarded to TRAUMAGEL based on expert reviews from hospital experts serving on Vizient's client-led councils. Vizient is the nation's largest provider-driven healthcare performance improvement company representing over $156 billion in annual purchasing volume.
  • McCarthy VetcoreChannel Partner/ Reseller/ Distributor · 16 June 2025McCarthy Vet is Cresilon's first veterinary distribution partner in Canada. McCarthy Vet, a family-owned company serving Canadian veterinarians for over 60 years, distributes VETIGEL directly to veterinary surgeons in Canada.
  • ZomedicaflagshipChannel Partner/ Reseller/ Distributor · 7 January 2025Zomedica has exclusive license to market and sell VETIGEL hemostatic gel in the U.S. and non-exclusive license internationally. Cresilon supplies product to Zomedica for distribution to U.S. customers through Zomedica's established field sales team and trade programs.
  • VerticalVetcoreChannel Partner/ Reseller/ Distributor · 11 June 2024Preferred Partnership Agreement providing VerticalVet's 1,800 GPO member veterinary clinics access to VETIGEL. VerticalVet is a Group Resource Community offering customized education, data insights, and tailored partner solutions.
  • CovetruscoreChannel Partner/ Reseller/ Distributor · 20 May 2024International distribution agreement for VETIGEL making the product available in Europe and the UK through Covetrus's distribution network.
  • Walter Reed Army Institute of Research (WRAIR)coreStrategic or Co-development Partner · 27 September 2022Cooperative Research and Development Agreement (CRADA) to study Cresilon's hemostatic gel technology as a potential field and prehospital treatment for penetrating traumatic brain injury (TBI). First phase preclinical study demonstrated promising safety and efficacy results.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Cresilon competitors and assessment

Company assessment

Market position

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Cresilon social profiles

Digital presence

Cresilon compliance and trust

Trust signal

Compliance3 records

Cresilon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cresilon leadership team

Management profile

Number of profiles

Profiles13 records

Cresilon funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cresilon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cresilon

What does Cresilon do?

Cresilon develops and manufactures proprietary plant-based hemostatic gel products that stop external bleeding in seconds. The portfolio includes TRAUMAGEL (30 mL pre-filled syringe, FDA 510(k) cleared for moderate-to-severe bleeding in EMS, trauma hospitals, military and law enforcement), VETIGEL (5 mL pre-filled syringe for veterinary surgical hemostasis), and Cresilon Hemostatic Gel (CHG) for minor cuts, lacerations and abrasions. All products leverage the same proprietary biopolymer hydrogel platform and are produced at the company's GMP-certified Brooklyn, NY biomanufacturing facility.

Is Cresilon a public or private company?

Cresilon is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cresilon founded?

Cresilon was founded in 2010. It employs 51 to 100 people.

Where is Cresilon based?

Cresilon is headquartered in Brooklyn, United States, in the North America region.

How does Cresilon make money?

Three revenue lines are on record. VETIGEL Product Sales are the primary driver. The others are TRAUMAGEL Product Sales and licensing & Supply Agreement with Zomedica.

Does Cresilon have an API?

No public API is recorded for Cresilon.

What industry is Cresilon in?

Cresilon's product category is Hemostatic Medical Devices. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAMAFAO, Practice Consumables & General Medical Supplies (Needles, Syringes, Gloves, Swabs). Its NAICS code is 325520 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceTRAUMAGEL Study Highlights Sustained Hemorrhage Control and Tourniquet Removal Without RebleedingCresilon announced a peer-reviewed study in the Journal of Special Operations Medicine evaluating TRAUMAGEL for hemorrhage control and tourniquet removal in three traumatic extremity cases. The study found sustained hemorrhage control and safe tourniquet removal without rebleeding. TRAUMAGEL is the first gel in a syringe with FDA 510(k) clearance for temporary external use.PR NewswireTRAUMAGEL Study Highlights Sustained Hemorrhage Control and Tourniquet Removal Without RebleedingCresilon announced a peer-reviewed study in the Journal of Special Operations Medicine evaluating TRAUMAGEL for hemorrhage control and tourniquet removal in three traumatic extremity cases. The study found sustained control without rebleeding, addressing prolonged tourniquet use risks. TRAUMAGEL is FDA-cleared and used by over 150 EMS agencies.openPR.comWound Closure Devices Market to Reach USD 28.13 Billion by 2032, Growing at a 7.52% CAGR Driven by Rising Surgical Volumes and Advancements in Closure Technologies | DelveInsightDelveInsight projects the global wound closure devices market to grow from USD 15,831.38 million in 2024 to USD 28,128.89 million by 2032, representing a CAGR of 7.52% during the 2025–2032 forecast period, driven by rising chronic wound prevalence, increasing surgical volumes, and technological advancements. Key growth drivers include the rising burden of chronic conditions such as diabetes and obesity, the expanding volume of surgical procedures worldwide, and innovations in bioabsorbable sutures, antimicrobial-coated devices, tissue adhesives, and AI-powered surgical systems. Recent market activities include Johnson & Johnson launching the ECHELON LINEAR Cutter with 3D-Stapling Technology, Merit Medical acquiring Biolife Delaware, and Cresilon receiving FDA approval for Traumagel.Inc.How a 17-Year-Old’s Science Fair Project Became a Life-Saving RealityJoe Landolina, as a 17-year-old NYU freshman in 2010, developed a plant-based hemostatic gel through a school competition that has since evolved into Cresilon, a bioengineering company now headquartered in Brooklyn's Industry City with over 100 employees. The company's Traumagel product creates a mechanical barrier inside wounds to stop bleeding in seconds without manual pressure, addressing a critical medical need that contributes to over 5 million deaths annually from uncontrolled bleeding. First responders are increasingly adopting the technology, with body camera footage documenting successful use of the gel when traditional methods like tourniquets proved ineffective.Adam MendlerInterview: Joe Landolina, Co-founder and CEO of CresilonJoe Landolina, co-founder and CEO of Cresilon, discusses the development and growth of his company's product TRAUMAGEL, an algae-derived polymer used to stop bleeding. The article highlights Cresilon's strategic decision to become its own manufacturer in Brooklyn to control quality and supply chain, enabling adoption across more than 150 EMS and trauma systems in 25 states.PR NewswireCresilon Named One of the World's 50 Most Innovative Companies by Fast CompanyCresilon, a Brooklyn-based biotechnology company, has been named to Fast Company's World's 50 Most Innovative Companies of 2026, ranking No. 1 in the medical devices category and No. 46 overall, marking the second time the company has earned the top spot in its category. TRAUMAGEL received FDA clearance in August 2024, launched nationwide in January 2025, and clinical reports indicate the hemostatic device saved at least one life per day on average throughout 2025. The company has expanded its manufacturing footprint to 55,000 square feet and the product is being evaluated by the U.S. military after being fielded by select units.YahooCresilon Named One of the World's 50 Most Innovative Companies by Fast CompanyCresilon was named to Fast Company's World's 50 Most Innovative Companies of 2026, ranking No. 1 in medical devices and No. 46 overall. Its TRAUMAGEL product received FDA clearance in August 2024 and launched nationwide in January 2025, with clinical use cases reporting at least one life saved per day on average in 2025.Fast CompanyHow this hemostatic gel stops potentially lethal bleeding in secondsCresilon has developed Traumagel, a hemostatic gel that can be administered via syringe to stop bleeding in seconds, which has been adopted by over 125 trauma and EMS systems across 25 states. Cleared by the FDA in August 2024, Traumagel is set to increase production to 100,000 units per month by mid-2027 due to high demand. The product's rapid adoption is credited with helping save numerous lives in emergency situations.BioSpaceCresilon Announces Poster Presentation on TRAUMAGEL Case Study at the 2026 Advanced Trauma Life Support Global SymposiumCresilon Inc., a Brooklyn-based biotechnology company, announced that a retrospective clinical case series demonstrating the use of its TRAUMAGEL hemostatic gel in emergency hemorrhagic trauma settings has been selected for a poster presentation at the 2026 ATLS Global Symposium in Birmingham, Alabama. The presentation will feature prehospital hemorrhage control data and include a poster session where Cresilon representatives will discuss clinical applications of the product. The ATLS Global Symposium is an annual international conference hosted by the American College of Surgeons Committee on Trauma.PR NewswireCresilon Announces Poster Presentation on TRAUMAGEL Case Study at the 2026 Advanced Trauma Life Support Global SymposiumCresilon Inc., a Brooklyn-based biotechnology company, announced that a retrospective clinical case series on its TRAUMAGEL hemostatic product has been selected for a poster presentation at the 2026 ATLS Global Symposium in Birmingham, Alabama. The presentation will demonstrate the use of TRAUMAGEL in prehospital emergency hemorrhagic trauma settings, with Cresilon representatives available to discuss clinical applications during the session. The symposium, hosted by the American College of Surgeons Committee on Trauma, is an annual international conference focused on advancing trauma care through education and research.